Contact
searchSearch
HMP Global
Login

NANETS Highlights: Updates in Clinical Development of Next-Generation Radioligand Therapies

Video Thumbnail
Videos
The Current NET Treatment Landscape and Unmet Needs
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts review the evolving treatment landscape for neuroendocrine tumors (NETs), highlighting approved systemic and liver-directed therapies and ongoing challenges in treatment sequencing.
Experts review the evolving treatment landscape for neuroendocrine tumors (NETs), highlighting approved systemic and liver-directed therapies and ongoing challenges in treatment sequencing.
Experts review the evolving...
11/18/2025
Oncology
Video Thumbnail
Videos
Examining the Evidence for Lutetium-Based PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts discuss data from pivotal trials that evaluated progression-free survival outcomes, treatment sequencing, and considerations for first-line PRRT use.
Experts discuss data from pivotal trials that evaluated progression-free survival outcomes, treatment sequencing, and considerations for first-line PRRT use.
Experts discuss data from...
11/18/2025
Oncology
Video Thumbnail
Videos
Practical Application and Patient Selection for PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor...
11/18/2025
Oncology
Video Thumbnail
Videos
Mechanism of Action: Beta vs Alpha Emitters
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and...
11/18/2025
Oncology
Video Thumbnail
Videos
Emerging Data on Alpha-Emitter Therapies
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving...
11/18/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use